Update on Chemotherapy in the Treatment of Urothelial Carcinoma
Urothelial carcinoma is the fifth most common malignancy diagnosed each year in the United States. Neoadjuvant and adjuvant chemotherapy are given to decrease the risk of recurrent or metastatic disease with the more robust clinical data supporting the former. Bladder preservation utilizes a trimoda...
Saved in:
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1100/2011/590175 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832567604789641216 |
---|---|
author | Carrie Costantini Frederick Millard |
author_facet | Carrie Costantini Frederick Millard |
author_sort | Carrie Costantini |
collection | DOAJ |
description | Urothelial carcinoma is the fifth most common malignancy diagnosed each year in the United States. Neoadjuvant and adjuvant chemotherapy are given to decrease the risk of recurrent or metastatic disease with the more robust clinical data supporting the former. Bladder preservation utilizes a trimodality approach with maximal transurethral resection followed by concurrent chemotherapy and radiation and is appropriate for select patients. Gemcitabine and cisplatin is the current standard of care for first-line treatment in fit patients with metastatic disease. Optimal second-line therapy remains undefined, and targeted agents are under investigation. Clinical trial participation should be encouraged in patients with urothelial carcinoma of the bladder to help improve treatment regimens and outcomes. Synopsis. Chemotherapy is commonly used in the treatment of urothelial carcinoma of the bladder. This paper will review the role of chemotherapy in the neoadjuvant, adjuvant, bladder sparing, and metastatic settings. |
format | Article |
id | doaj-art-a7acd550e5c042ed8ae2b5302fb876f6 |
institution | Kabale University |
issn | 1537-744X |
language | English |
publishDate | 2011-01-01 |
publisher | Wiley |
record_format | Article |
series | The Scientific World Journal |
spelling | doaj-art-a7acd550e5c042ed8ae2b5302fb876f62025-02-03T01:01:11ZengWileyThe Scientific World Journal1537-744X2011-01-01111981199410.1100/2011/590175590175Update on Chemotherapy in the Treatment of Urothelial CarcinomaCarrie Costantini0Frederick Millard1Moores UCSD Cancer Center, University of California, San Diego, 3855 Health Sciences Drive Mail Code 0987, San Diego, CA 92093-0987, USAMoores UCSD Cancer Center, University of California, San Diego, 3855 Health Sciences Drive Mail Code 0987, San Diego, CA 92093-0987, USAUrothelial carcinoma is the fifth most common malignancy diagnosed each year in the United States. Neoadjuvant and adjuvant chemotherapy are given to decrease the risk of recurrent or metastatic disease with the more robust clinical data supporting the former. Bladder preservation utilizes a trimodality approach with maximal transurethral resection followed by concurrent chemotherapy and radiation and is appropriate for select patients. Gemcitabine and cisplatin is the current standard of care for first-line treatment in fit patients with metastatic disease. Optimal second-line therapy remains undefined, and targeted agents are under investigation. Clinical trial participation should be encouraged in patients with urothelial carcinoma of the bladder to help improve treatment regimens and outcomes. Synopsis. Chemotherapy is commonly used in the treatment of urothelial carcinoma of the bladder. This paper will review the role of chemotherapy in the neoadjuvant, adjuvant, bladder sparing, and metastatic settings.http://dx.doi.org/10.1100/2011/590175 |
spellingShingle | Carrie Costantini Frederick Millard Update on Chemotherapy in the Treatment of Urothelial Carcinoma The Scientific World Journal |
title | Update on Chemotherapy in the Treatment of Urothelial Carcinoma |
title_full | Update on Chemotherapy in the Treatment of Urothelial Carcinoma |
title_fullStr | Update on Chemotherapy in the Treatment of Urothelial Carcinoma |
title_full_unstemmed | Update on Chemotherapy in the Treatment of Urothelial Carcinoma |
title_short | Update on Chemotherapy in the Treatment of Urothelial Carcinoma |
title_sort | update on chemotherapy in the treatment of urothelial carcinoma |
url | http://dx.doi.org/10.1100/2011/590175 |
work_keys_str_mv | AT carriecostantini updateonchemotherapyinthetreatmentofurothelialcarcinoma AT frederickmillard updateonchemotherapyinthetreatmentofurothelialcarcinoma |